Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data from the Canadian Kidney Cancer Information System (CKCis) database.

This article has no abstract
Epistemonikos ID: bdc3d9c289ae766e8f896b13fc702e275f4bc4cb
First added on: May 09, 2026